Pharsight

1. Pataday Once Daily Relief patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9533053	December, 2019	Terminated-Denied	Novartis AG	AYLA PHARMA LLC
US8791154	June, 2018	Terminated-Settled	Alcon Research Ltd.	Cipla Limited
US9533053	June, 2018	Terminated-Settled	Alcon Research Ltd.	Cipla Limited
US8791154	August, 2016	Terminated-Settled	Alcon Research, Ltd.	Apotex, Inc.
US8791154	February, 2016	Terminated-Settled	Alcon Research, Ltd.	Argentum Pharmaceuticals, LLC

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5641805	ALCON LABS INC	Topical ophthalmic formulations for treating allergic eye diseases	Jun, 2015 (8 years ago)
US5641805 (Pediatric)	ALCON LABS INC	Topical ophthalmic formulations for treating allergic eye diseases	Dec, 2015 (8 years ago)
US7402609	ALCON LABS INC	Olopatadine formulations for topical administration	Jun, 2022 (1 year, 10 months ago)
US7402609 (Pediatric)	ALCON LABS INC	Olopatadine formulations for topical administration	Dec, 2022 (1 year, 4 months ago)
US6995186	ALCON LABS INC	Olopatadine formulations for topical administration	Nov, 2023 (5 months ago)
US6995186 (Pediatric)	ALCON LABS INC	Olopatadine formulations for topical administration	May, 2024 (10 days from now)
US8791154	ALCON LABS INC	High concentration olopatadine ophthalmic composition	May, 2032 (8 years from now)
US9533053	ALCON LABS INC	High concentration olopatadine ophthalmic composition	May, 2032 (8 years from now)

Market Authorisation Date: 22 December, 2004

Treatment: Method of treating allergic conjunctivitis; Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.002	08 Sep, 2008	1	13 Jul, 2015	12 Nov, 2023	Eligible
0.007	10 Sep, 2015	1	19 Feb, 2020	19 May, 2032	Non-forfeiture

Strength	Dosage	Availability
EQ 0.2% BASE	SOLUTION/DROPS;OPHTHALMIC	Over the counter
EQ 0.7% BASE	SOLUTION/DROPS;OPHTHALMIC	Over the counter

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5641805	ALCON LABS INC	Topical ophthalmic formulations for treating allergic eye diseases	Jun, 2015 (8 years ago)
US5641805 (Pediatric)	ALCON LABS INC	Topical ophthalmic formulations for treating allergic eye diseases	Dec, 2015 (8 years ago)

Market Authorisation Date: 18 December, 1996

Treatment: Treating allergic eye diseases in humans

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.001	17 Jul, 2006	1	07 Dec, 2015	06 Jun, 2015	Extinguished

Strength	Dosage	Availability
EQ 0.1% BASE	SOLUTION/DROPS;OPHTHALMIC	Over the counter

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399508	NOVARTIS	Olopatadine formulations for topical nasal administration	Sep, 2022 (1 year, 7 months ago)
US7977376	NOVARTIS	Olopatadine formulations for topical nasal administration	Feb, 2023 (1 year, 2 months ago)
US8399508 (Pediatric)	NOVARTIS	Olopatadine formulations for topical nasal administration	Mar, 2023 (1 year, 1 month ago)
US7977376 (Pediatric)	NOVARTIS	Olopatadine formulations for topical nasal administration	Aug, 2023 (8 months ago)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Jun 01, 2013
New Patient Population(NPP)	Dec 01, 2012

Market Authorisation Date: 15 April, 2008

Treatment: Allergic rhinitis

Dosage: SPRAY, METERED;NASAL